Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 9 Depression 9 Anxiety Disorders 7 Neoplasm Metastasis 3 Melanoma 2 Depressive Disorder, Major 2 Wounds and Injuries 1 Trauma, Nervous System 1 Stress Disorders, Post-Traumatic 1 Pancreatic Neoplasms 1 Pain 1 Ovarian Neoplasms 1 Osteosarcoma 1 Opioid-Related Disorders 1 Lymphoma 1 Hospice 1 Hematopoietic and Lymphatic System Neoplasm 1 Hematologic Neoplasms 1 Gastrointestinal Neoplasms 1 Endocrine Gland Neoplasms 1 Depressive Disorder 1 Caregiver Distress 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Biliary Tract Neoplasms 1 Agnosia 1

Interventions

Standard of Care 2 salicylhydroxamic acid 1 methylnaltrexone 1 acetaminophen, codeine drug combination 1 X-Rays 1 Ultrasonic Waves 1 Tramadol 1 Tirzepatide 1 Therapeutics 1 Sublocade 1 Radiography, Abdominal 1 Psilocybin 1 Olanzapine 1 Morphine 1 Midazolam 1 Methadone 1 Medical Marijuana 1 Lidocaine 1 Hematologic Tests 1 Educational Status 1 Dosage Forms 1 Capsules 1 Buprenorphine, Naloxone Drug Combination 1 Buprenorphine 1 Blood Specimen Collection 1 Acetaminophen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Opioid-Related Disorders × Psilocybin × Clear all

NCT06001749 2025-12-16

Psilocybin in Cancer Pain Study

Dana-Farber Cancer Institute

Phase 2 Recruiting

Agnosia, Opioid-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡